Melanotan II
$44.99
In stockMelanotan II, also called Melanotan 2 or MT-II, is an investigational synthetic peptide that mimics aspects of alpha-melanocyte-stimulating hormone (alpha-MSH). It activates melanocortin receptors involved in skin pigmentation and other biological functions. Research has examined its effects on pigmentation, erectile responses, and sexual desire.
| SKU | RC-ST-MT2-10MG |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 10 mg |
| Size | 3 mL Vial |
| Reported Result | See matching batch report |
| Stock | In stock |
| Documentation Status | Client-supplied report available |
Product Description
Melanotan II, also called Melanotan 2 or MT-II, is an investigational synthetic peptide that mimics aspects of alpha-melanocyte-stimulating hormone (alpha-MSH). It activates melanocortin receptors involved in skin pigmentation and other biological functions. Research has examined its effects on pigmentation, erectile responses, and sexual desire.
Its pigmentation effects involve signaling that stimulates production of eumelanin, a pigment responsible for darker skin coloration. Because Melanotan II activates multiple melanocortin receptors, its effects extend beyond the skin.
What research has shown:
Preliminary pigmentation findings: An early phase I pilot study investigated subcutaneous Melanotan II and reported increased skin pigmentation. The study was very small and does not establish a reliable cosmetic benefit or long-term safety.
Erectile responses in humans: A double-blind, placebo-controlled crossover study involving 10 men with psychogenic erectile dysfunction found clinically apparent erections in eight participants after Melanotan II.
Changes in sexual desire: Small human investigations reported increased sexual desire more frequently after Melanotan II than placebo, alongside frequent nausea and yawning.
Storage and handling: Keep sealed, dry, and protected from heat and direct light unless the final product label or COA states otherwise. Maintain the product with its matching batch record.
Third-party testing status.
| Batch / Lot | Reported Result | Tested | Partner | Status | Document |
|---|---|---|---|---|---|
| ML10/2025-12-18-B | 99.683%; 99.662% | Jan 5, 2026 | Janoshik | Client-supplied report | View COA |
.png)